337 related articles for article (PubMed ID: 31265470)
1. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
[TBL] [Abstract][Full Text] [Related]
2. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon.
Ngangue YR; Mbuli C; Neh A; Nshom E; Koudjou A; Palmer D; Ndi NN; Qin ZZ; Creswell J; Mbassa V; Vuchas C; Sander M
J Clin Microbiol; 2022 Aug; 60(8):e0015522. PubMed ID: 35861529
[TBL] [Abstract][Full Text] [Related]
4. Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.
Khaparde S; Raizada N; Nair SA; Denkinger C; Sachdeva KS; Paramasivan CN; Salhotra VS; Vassall A; Hoog AV
PLoS One; 2017; 12(9):e0184270. PubMed ID: 28880875
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
Andrews JR; Lawn SD; Rusu C; Wood R; Noubary F; Bender MA; Horsburgh CR; Losina E; Freedberg KA; Walensky RP
AIDS; 2012 May; 26(8):987-95. PubMed ID: 22333751
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study.
Reddy KP; Gupta-Wright A; Fielding KL; Costantini S; Zheng A; Corbett EL; Yu L; van Oosterhout JJ; Resch SC; Wilson DP; Horsburgh CR; Wood R; Alufandika-Moyo M; Peters JA; Freedberg KA; Lawn SD; Walensky RP
Lancet Glob Health; 2019 Feb; 7(2):e200-e208. PubMed ID: 30683239
[TBL] [Abstract][Full Text] [Related]
7. Multicentric validation of indigenous molecular test Truenat™ MTB for detection of
Gomathi NS; Singh M; Singh UB; Myneedu VP; Chauhan DS; Sarin R; Mohan A; Bhatnagar A; Khangembam JS; Kannan T; Rao MVV; Logani J; Dey B; Gangakhedkar RR; Swaminathan S; Tripathy S
Indian J Med Res; 2020 Oct; 152(4):378-385. PubMed ID: 33380702
[TBL] [Abstract][Full Text] [Related]
8. Microscopic observation drug-susceptibility assay vs. Xpert
Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
[TBL] [Abstract][Full Text] [Related]
9. Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients.
Gomathi NS; Singh M; Myneedu VP; Chauhan DS; Tripathy S; Sarin R; Mohan A; Bhatnagar A; Khangembam JS; Kannan T; V Rao MV; Logani J; Dey B; Gangakhedkar RR; Swaminathan S; Singh UB
Indian J Med Res; 2020 Nov; 152(5):482-489. PubMed ID: 33707390
[TBL] [Abstract][Full Text] [Related]
10. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
[TBL] [Abstract][Full Text] [Related]
11. A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
Penn-Nicholson A; Gomathi SN; Ugarte-Gil C; Meaza A; Lavu E; Patel P; Choudhury B; Rodrigues C; Chadha S; Kazi M; Macé A; Nabeta P; Boehme C; Gangakhedkar RR; Sarin S; Tesfaye E; Gotuzzo E; du Cros P; Tripathy S; Ruhwald M; Singh M; Denkinger CM; Schumacher SG; ;
Eur Respir J; 2021 Oct; 58(5):. PubMed ID: 34049948
[TBL] [Abstract][Full Text] [Related]
12. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, Ethiopia.
Meaza A; Tesfaye E; Mohamed Z; Zerihun B; Seid G; Eshetu K; Amare M; Sinshaw W; Dagne B; Mollalign H; Diriba G; Getu M; Yenew B; Tadesse M; Fikadu D; Abebaw Y; Moga S; Kebede A; Tola HH; Alemu A; Getahun M; Gumi B
PLoS One; 2021; 16(12):e0261084. PubMed ID: 34962949
[TBL] [Abstract][Full Text] [Related]
14. The New Xpert MTB/RIF Ultra: Improving Detection of
Chakravorty S; Simmons AM; Rowneki M; Parmar H; Cao Y; Ryan J; Banada PP; Deshpande S; Shenai S; Gall A; Glass J; Krieswirth B; Schumacher SG; Nabeta P; Tukvadze N; Rodrigues C; Skrahina A; Tagliani E; Cirillo DM; Davidow A; Denkinger CM; Persing D; Kwiatkowski R; Jones M; Alland D
mBio; 2017 Aug; 8(4):. PubMed ID: 28851844
[TBL] [Abstract][Full Text] [Related]
15. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: a pragmatic, cluster-randomized controlled trial to evaluate the effect of implementation of the Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania (TB-CAPT CORE).
Leukes VN; Hella J; Sabi I; Cossa M; Khosa C; Erkosar B; Mangu C; Siyame E; Mtafya B; Lwilla A; Viegas S; Madeira C; Machiana A; Ribeiro J; Garcia-Basteiro AL; Riess F; Elísio D; Sasamalo M; Mhalu G; Denkinger CM; Castro MDM; Bashir S; Schumacher SG; Tagliani E; Malhotra A; Dowdy D; Schacht C; Buech J; Nguenha D; Ntinginya N; Ruhwald M; Penn-Nicholson A; Kranzer K;
BMC Infect Dis; 2024 Jan; 24(1):107. PubMed ID: 38243223
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil.
Pinto M; Steffen RE; Cobelens F; van den Hof S; Entringer A; Trajman A
Int J Tuberc Lung Dis; 2016 May; 20(5):611-8. PubMed ID: 27084814
[TBL] [Abstract][Full Text] [Related]
18. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
[TBL] [Abstract][Full Text] [Related]
20. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
